Colchicine reduces the risk of COVID-19-related complications
The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance
View the full story here: https://financialpost.com/globe-newswire/colchicine-reduces-the-risk-of-covid-19-related-complications-positive-results-from-colcorona-trial-show-that-colchicine-is-the-only-effective-oral-medication-for-treating-non-hospitalized-patients
